Treatment in Autoimmune Disease
Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune disease. Our proprietary immune tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted disease therapy, without the side effects of broad immunosuppression. Anokion’s antigen-specific platform can be translated to virtually any antigen-mediated disease, with widespread potential across multiple clinical applications.
- January 16, 2019
Anokion Expands Leadership Team with Appointment of Simon Cooper, MBBS, as Chief Medical Officer| Read More
- June 14, 2018
Anokion Expands Leadership Team with Appointment of Deborah Geraghty, Ph.D., as Chief Business Officer| Read More